Optimising Outcomes for the TAVI Patient: Key Considerations for First Valve Choice and Implantation Techniques

Published: 11 April 2022

  • Views:

    Views Icon 4473
  • Likes:

    Heart Icon 7

Overview

In this symposium, part of Transcatheter Interventions Online 2022, we review latest data showing why durability and hemodynamics matter for initial valve selection and discuss the latest techniques to help achieve optimal outcomes for patients with longer life expectancy.

 

Join this expert faculty for a combination of highly informative technical presentations and patient case studies.

This symposium has been supported by an unrestricted educational grant by Medtronic.

Key Learning Objectives

  • Recall the latest data showing why durability and hemodynamics matter for initial valve selection.
  • Discuss the latest techniques to help achieve optimal outcomes for patients with longer life expectancy.

Target Audience

  • Interventional Cardiologists
  • Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
  • Interventional Cardiology Nurses

More from this programme

Part 1

Considerations for First Valve Choice

In this first chapter, Prof Ran Kornowski drives us through the reason why the choice of the first valve is important, and what physicians look for when planning and preparing a TAVI procedure. Prof Kornowski will review the short-term and long term considerations.

Part 2

Optimised Approaches for First Valve Choice

In this chapter Prof Lars Søndergaard looks at the procedural steps to optimise the outcome for TAVI patients, and how physicians refine the steps based on longer lifetime expectancy.

Part 3

Tips and Tricks for Achieving Procedure Efficiencies

In the final chapter of the symposium, Dr Douglas Fraser dives into the tips and tricks relating to his own experience. Dr Fraser then discusses contemporary techniques to optimise outcomes for patients.

Faculty Biographies

Lars Søndergaard

Lars Søndergaard

Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).

View full profile